Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

Taking the leap as a solo developer in Sweden’s growing game industry

Jacques Diringer left a secure job at the game giant King to follow his dream of creating his own game from scratch. In a Stockholm where the gaming industry is growing rapidly and new companies are launched every year, he now embarks on a more uncertain but creative journey. The path has been both challenging and inspiring, shaped by a vibrant gaming community, new collaborations, and the courage to trade stability for freedom.

Steps shaping innovation and growth – Natasha Bank sums up the first year of Life Science Cluster Flemingsberg

A future life science cluster isn’t built in a year – but with a solid foundation and the courage to act, important steps can be taken along the way. In February 2025, we launched Life Science Cluster Flemingsberg: a multifaceted project with powerful, interconnected ambitions – to enable Flemingsberg’s life science cluster to reach its full potential by collaboration and creating the right conditions for the establishment and growth of those who drive innovation – small and medium-sized enterprises – and, in doing so, contribute to the Stockholm region’s leading position within the sector.

Johnny Högberg Summarizes 2025 – A Year of Growth and Collaboration in Flemingsberg

We are most effective and make the greatest impact when we engage our founders and leverage their size, organizations, and influence, and we still strongly believe in this. At the same time, the fact that we have grown as an organization has also made a difference. Today, we are exactly the kind of “two-pizza team” that Amazon founder Jeff Bezos highlights as the most effective. Among other things, we are now running two cluster initiatives and creating a level of engagement, buzz, and content that is noticeable in Flemingsberg and is actually helping to change the area.